OncoResponse, a biotech start-up which develops cancer immunotherapies, has raised $40m in series B funding. The investment came from a combination of existing partners, including Alexandria Venture Investments, Arch Venture Partners, HT Family Office, as well as new investors Redmile Group and the Qatar Investment Authority. OncoResponse said the money will be used to continue developing five of the company's therapy programs, which are based on antibodies from cancer patients in remission. The company expects to begin clinical trials by the following year, with the new funding securing the company financially until the end of 2020.
OncoResponse, a biotech start-up which develops cancer immunotherapies, has raised $40m in series B funding. The investment came from a combination of existing partners, including Alexandria Venture Investments, Arch Venture Partners, HT Family Office, as well as new investors Redmile Group and the Qatar Investment Authority. OncoResponse said the money will be used to continue developing five of the company's therapy programs, which are based on antibodies from cancer patients in remission. The company expects to begin clinical trials by the end of 2020, with the new funding securing the company financially until the following year.